Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by di Sant'Agnese, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by di Sant'Agnese, P. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:S135-S140, 2001
© 2001 European Society for Medical Oncology

Reviews

Neuroendocrine differentiation in prostatic carcinoma: An update on recent developments

P. A. di Sant'Agnese

University of Rochester Medical Center Rochester, New York, USA

Correspondence to: P. A. di Sant'Agnese, MD University of Rochester Medical Center Department of Pathology Box 626 Rochester, NY 14642 USA

The most recent developments relating to neuroendocrine differentiation in prostate cancer are reviewed. In vivo and in vitro experimental models of neuroendocrine differentiation in prostate cancer are emphasized with a discussion of their fidelity to the actual human in vivo situation. The contribution of these models to our understanding of the process of neuroendocrine differentiation and the mechanisms by which neuroendocrine differentiation can affect prognosis is discussed. Finally, an hypothosis is proprosed integrating neuroendocrme differentiation into more traditional models of the evolution, differentiation pathways and progression of prostate cancer, particularly in the androgen independent state.

chromogranin, neuroendocrine, neuroendocrine cells, neuroendocrine differentiation, prostate, prostate cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
F. Vignani, L. Russo, M. Tucci, M. Motta, G. Vellani, M. Tampellini, M. Papotti, L. Dogliotti, and A. Berruti
Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen
Ann. Onc., December 1, 2009; 20(12): 2019 - 2020.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Deng, H. Liu, J. Huang, L. Cheng, E. T. Keller, S. J. Parsons, and C.-D. Hu
Ionizing Radiation Induces Prostate Cancer Neuroendocrine Differentiation through Interplay of CREB and ATF2: Implications for Disease Progression
Cancer Res., December 1, 2008; 68(23): 9663 - 9670.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-P. Liao, C. Zhong, G. Saribekyan, J. Bading, R. Park, P. S. Conti, R. Moats, A. Berns, W. Shi, Z. Zhou, et al.
Mouse Models of Prostate Adenocarcinoma with the Capacity to Monitor Spontaneous Carcinogenesis by Bioluminescence or Fluorescence
Cancer Res., August 1, 2007; 67(15): 7525 - 7533.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A Berruti, A Mosca, M Tucci, C Terrone, M Torta, R Tarabuzzi, L Russo, C Cracco, E Bollito, R M Scarpa, et al.
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease
Endocr. Relat. Cancer, March 1, 2005; 12(1): 109 - 117.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.